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tions between the patient numbers by months in physiotherapy care and the 
prevalence of fracture development. The authors suggest structuring the health 
care system and distributing resources to follow the needs supported by our 
findings.
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Objectives: Gout, a chronic inflammatory arthritis, can result in extensive medi-
cal problems due to painful flares and joint damage resulting from the build-up of 
tophi (deposits of uric acid crystals). The prevalence of gout is rising, which is likely 
to increase the burden of the disease. We determined the current cost impacts 
of gout and identified key disease burden factors. We also aimed to highlight 
data gaps for further investigation. MethOds: A systematic literature review was 
conducted using the MEDLINE database and The Cochrane Library. Articles pub-
lished in English between January 2000 and July 2014 that reported the economic 
burden (in terms of either direct or indirect costs) were identified, and patient 
and cost data were collated, with key themes and data gaps identified. Results: 
Of the 323 studies identified, 13 primary studies were relevant to the economic 
burden of gout. Key variables included serum uric acid levels, presence of tophi 
and number of flares, which resulted in high healthcare resource use that was 
frequently attributed to hospitalisation and inpatient stay. The incremental direct 
cost of gout was reported to be up to US$21,467 per annum, in cases where patients 
were experiencing regular acute flares with the presence of tophi. cOnclusiOns: 
Patient-level costs associated with the treatment and clinical management of 
gout can be substantial, depending on disease severity. The identified studies 
were dominated by direct cost analyses; only three studies specifically considered 
indirect costs. There was a paucity of non-US data, and there was a lack of pub-
lished studies estimating the population-wide cost. Despite the limited published 
data, the review identified a growing number of publications in this area in the 
last 5 years, suggesting healthcare decision makers’ increasing awareness of the 
wider impacts of gout.
PMS127
ReliABility of MAnufActuReRS’ BudGet iMPAct eStiMAteS foR SeveRe 
RheuMAtoid ARthRitiS dRuGS in PolAnd
Zawodnik S1, Tatara T1, Iwanczuk T1, Sliwczynski A2, Brzozowska M2
1Agency for Health Technology Assessment and Tariff System in Poland (AOTMiT), Warsaw, 
Poland, 2Medical University of Lodz, Lodz, Poland
Objectives: To compare the total value of payer’s expenditures on Cimzia (cer-
tolizumab pegol) and RoActemra (tocilizumab) in patients with severe rheumatoid 
arthritis estimated in the manufacturers’ Budget Impact Analyses (BIAs) submitted 
with the reimbursement applications to AOTMiT and actual expenditures of the 
National Health Fund (NHF). MethOds: Annual public payer’s expenditures esti-
mated in manufacturers’ BIAs for Cimzia and RoActemra and actual expenditures 
reported by the NHF were compared. RSSs were not taken into account. Analysed 
drugs were chosen on the basis of the same indication and financing through 
the same therapeutic programme in Poland. Actual expenditures and population 
size were taken from the financial reports of the NHF for the first and second 
year (actual data on 11 months for expenditures were extrapolated to one year) 
of reimbursement for each drug. Results: For drugs Cimzia and RoActemra in 
patients with severe rheumatoid arthritis, the sum of total expenditures estimated 
in BIAs submitted with the reimbursement applications was 18,04 million PLN in 
the first year and 28,47 million PLN in the second year, and they were lower than 
the actual expenditures reported by the NHF: 20,03 million PLN and 36,51 million 
PLN, respectively. The expenditures estimated in BIAs were underestimated by 10% 
in the first year of reimbursement and 22% in the second year of reimbursement. 
Population size estimated in BIAs in comparison to its actual size from the NHF 
reports was underestimated by 61% in the first year and 57% in the second year 
of reimbursement. cOnclusiOns: In the case of drugs chosen for this analysis, 
total payer’s expenditures estimated in BIAs submitted with the reimbursement 
applications were underestimated in comparison to the real life expenditures of 
the NHF in Poland.
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Objectives: Osteoporosis is one of the commonest bone diseases in which bone 
fragility is increased. There are several possibilities for the prevention of primary, 
secondary and tertiary osteoporosis but until now they have not been promoted 
enough and bone fragility is thought about only after the onset of a fracture (ter-
tiary prevention). Preventative strategies against osteoporosis can be aimed at 
either optimizing the peak bone mass obtained, or reducing the rate of bone 
loss. Optimization of peak bone mass may be more amenable to public health 
strategies. MethOds: A group of patients over 50 year old that has been treated 
with medicines included in the AIFA Note 79 during a period of 5 years is studied 
in comparison with a similar group that has not been treated with medicines 
included in the AIFA Note 79 for the same period time. For both groups are also 
extracted inpatient and outpatient medical records and medicine prescriptions. 
Only patients treated for at least three years are considered significant. To avoid 
confounding the resulting data were standardized and stratified. Results: The 
total expenditure for patients compliant with therapy who have had access to the 
hospital is less than twenty-eight percent compared to the total expenditure for 
patients not receiving therapy or not compliant. cOnclusiOns: Osteoporosis is 
undersupplied, even though they have a higher charlson-comorbidity index. Still, 
this study may not clarify whether this is due to costs or patient and physician 
preference.
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Objectives: The aim of this study is to perform gender specific analysis regard-
ing the persistence to antiosteoporotic drugs by using administrative data-
bases. MethOds: The data used for this study were obtained from outpatient 
drug prescriptions, hospital discharges and ambulatory care records collected 
from January 1, 2005 to December 31, 2008. The study was designed as a retrospec-
tive study cohort. Patients 60 years of age or older were included if at least one 
prescription for any antiosteoporotic drugs had been filled in between January 
1, 2006 and December 31, 2006. Persistence was defined as the length of time 
in days from the date of the index prescription to the date of discontinuation 
therapy. Discontinuation was evaluated by using the gap method. Results: 
The final cohort consisted of a total of 7,867 patients (87.2% women). The mean 
patient age for both genders at the index date was 74.5 years. About one-fifth of 
all subjects had experienced with spot therapy, but men were more likely than 
women to have a spot therapy experience (45.4% vs. 14.5%). Approximately 6% 
of all included patients were switchers: Switching rates were highest for males 
(18.9%) and lower for female (4.4%). The crude analysis of long-term gender per-
sistence showed a significant difference between women and men users: the 
relative number of persistence patients after 1 year was 66.4% in men and 44.7% 
in women. The Kaplan Meier plots of time to persistence start to differ for men 
vs women approximately 60 days after treatment start. cOnclusiOns: Gender 
differences in medication taking behaviour is a relevant issue in drug utilization 
studies. Our analysis showed that women are more likely to be non-persistent 
than men in osteoporosis ttherapy.
PMS124
nuMBeR of oSteoPoRoSiS PAtientS with PAtholoGicAl fRActuReS By 
GendeR in outPAtient cARe in the liGht of PhySiotheRAPy cARe in 
hunGARy
Molics B1, Endrei D1, Rátgéber L2, Gyuró M1, Sebestyén A3, Juhász R1, Elmer D1, Boncz I1, 
Péter I4, Juhász K3, Járomi M1
1University of Pécs, Pécs, Hungary, 2Ratgeber Academia, Pécs, Hungary, 3National Health 
Insurance Fund Administration, Pécs, Hungary, 4Zsigmondy Vilmos SPA Hospital, Harkány, 
Hungary
Objectives: The aim of our study is to determine the number of osteoporosis 
patients with pathological fractures by gender in outpatient care based on physi-
otherapy activities. MethOds: The data come from the financial data base of the 
National Health Insurance Fund Administration (in Hungarian: OEP) involving 
the year of 2013. The activity list was provided by the rulebook on the application 
of the activity code list in out-patient care. The osteoporosis with pathological 
fractures is listed in the International Classification of Diseases (ICD) with code 
of M80. Population distribution was taken into account on the basis of the data 
of the Central Statistical Office from January 1st 2013. Results: Based on 151 
physiotherapy activities, the annual patient numbers accounted for 39725 per-
sons in the total population. The patient numbers accounted for 2544 persons 
for males and 37181 persons for females (10,000 per capita the patient num-
bers were 40 persons for the total population, 5 persons for males and 72 for 
females). cOnclusiOns: The higher patient numbers for females can be clearly 
associated with the prevalence of the basic disease. The total value for the patient 
numbers by months is higher caused by the aftercare of the same patients that 
still lasts in the following month. The authors suggest structuring the health 
care system and distributing resources to follow the needs supported by our 
findings.
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Objectives: The aim of our study is to determine the number of osteoporosis 
patients with pathological fractures by months in outpatient care based on physi-
otherapy activities. MethOds: The data come from the financial data base of 
the National Health Insurance Fund Administration (in Hungarian: OEP) covering 
the year of 2013. The activity list was provided by the rulebook on the applica-
tion of the activity code list in out-patient care. The osteoporosis with patho-
logical fractures is listed in the International Classification of Diseases (ICD) 
with code of M80. Results: Based on 151 physiotherapy activities, the annual 
patient numbers accounted for 85142 persons in the total population by months. 
The patient numbers accounted for 5063 persons for males and 80079 persons 
for females. The patient numbers were 86 persons for the total population, 11 
persons for males and 154 for females per 10,000 capita. The patient numbers 
above average by months could be found in the spring and autumn months (aver-
age: population= 7095, males= 421, females= 6673). cOnclusiOns: The higher 
patient numbers for females can be clearly associated with the prevalence of 
the basic (osteoporosis) disease. It would be interesting to examine the correla-
